News

2025. 10. 15

New C2H Report: Zolbetuximab (Vyloy)

2025. 09. 10

New C2H Report: Luspatercept (Reblozyl)

2025. 07. 09

New C2H Report: lecanemab (Leqembi)

2025. 05. 14

New C2H Report: Semaglutide (Wegovy)

2025. 05. 14

New C2H Report: Inclisiran (Leqvio) 

2025. 05. 14

New C2H Report: Tenapanor (Phozevel)

2025. 04. 23

New C2H Report: Epcoritamab (EPKINLY)

2025. 02. 08

New C2H Report: Ritlecitinib tosylate (Litfulo)

2025. 02. 01

New C2H Report: the aortic stent graft (The GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System)

2025. 01. 15

Due to server and network equipment changeover work, the website will be unavailable all day on January 18 (Sat.) and 19 (Sun.).

2024. 10. 09

New C2H Report: Ropeginterferon Alfa-2b (Besremi)

2024. 10. 09

New C2H Report: Ensitrelvir (Xocova)

2024. 09. 11

New C2H Report: Tirzepatide (Mounjaro)

2024. 06. 12

New C2H Report: Tezepelumab (Tezspire)

2024. 04. 28

New C2H Report: Deucravacitinib (Sotyktu)

2024. 03. 13

New C2H Report: Molnupiravir (Lagevrio)

2024. 03. 13

New C2H Report: Finerenone (Kerendia)

2023. 12. 02

New C2H Report: Efgartigimod Alfa (Vyvgart)

2023. 11. 21

New C2H Report: Valbenazine (Dysval)

2023. 11. 04

New C2H Report: Bimekizumab (Bimzelx)

2023. 10. 29

New C2H Report: Andexanet alfa (Ondexxya)

2023. 09. 23

New C2H Report: Clazosentan (Pivlaz)

2023. 08. 30

New C2H Report: Selpercatinib (Retevmo)

2023. 07. 22

New C2H Report: Gefapixant (Lyfnua)

2023. 07. 22

New C2H Report: Expedium Verse Fenestrated Screw system

2023. 07. 22

New C2H Report: Micra AV (Micra transcatheter pacing system)

2023. 07. 15

New C2H Report: Enfortumab vedotin (Padcev)

2023. 07. 08

New C2H Report: Teduglutide (Revestive)

2023. 05. 11

New C2H Report: Galcanezumab (Emgality)

2023. 04. 13

New C2H Reports: Daratumumab Vorhyaluronidase Alfa (Darzquro) and Polatuzumab Vedotin (Polivy)

2023. 04. 04

New C2H Reports: Amikacin sulfate (Arikayce) and Remdesivir (Veklury)

2022. 05. 10

New guideline for cost-effectiveness evaluation in English

2022. 04. 26

New C2H Report: Trastuzumab deruxtecan (Enhertu)

2021. 06. 01

New C2H Report: Vortioxetine (Trintellix) and Ivabradine (Coralan)

2021. 04. 22

New C2H Report: Ravulizumab (Ultomiris)

2021. 03. 31

The first reports of the cost-effectiveness evaluation were released.

2019. 03. 22

Guidelines for analysis of cost-effectiveness evaluation published

2019. 03. 06

Materials from the International Symposium have been posted

2019. 02. 18

Our new website is open

2019. 01. 30

C2H holds international symposium

2018. 04. 01

C2H is newly established in NIPH.